Erratum: Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
Authors:
Published: 2023-06-26
DOI:
10.1200/jco.23.01239
Source:
Full article
Abstract
No abstract found.